Serologic markers in inflammatory bowel disease: tools for better diagnosis and disease stratification

@article{Dotan2007SerologicMI,
  title={Serologic markers in inflammatory bowel disease: tools for better diagnosis and disease stratification},
  author={Iris Dotan},
  journal={Expert Review of Gastroenterology \& Hepatology},
  year={2007},
  volume={1},
  pages={265 - 274}
}
  • I. Dotan
  • Published 1 December 2007
  • Medicine
  • Expert Review of Gastroenterology & Hepatology
In the last decade, new serologic markers have been identified, and attempts to delineate their potential roles in inflammatory bowel disease diagnosis, determination of prognosis and identification of apparently healthy subjects at risk have significantly increased our knowledge. In this review, the major serologic markers will be described, focusing on their common features as a group. It is predicted that within the next 5 years, panels of antibodies will prove to have a significant impact… 
Antibody markers in the diagnosis of inflammatory bowel disease.
TLDR
No single marker with qualities that are satisfactory for the diagnosis and treatment of IBD has been identified, although panels of some antibodies are being evaluated with keen interest, and the discovery of novel IBD-specific and sensitive markers is anticipated.
Clinical Utility of Biomarkers in IBD
TLDR
This overview is structured in chapters reflecting those four typical situations during the disease course of IBD patents to critically evaluate the potential and value of each of the biomarkers in the specific situation.
Serological Markers in Inflammatory Bowel Disease
TLDR
Serological markers linked to CD, such as anti-Saccaromyces cerevisiae, anti-Pseudomonas-associated sequence I2, outer membrane porin C of Escherichia coli antibodies and antibodies against the bacterial flagellin CBir1, as well as markers linked as perinuclear anti-neutrophil cytoplasmic antibodies, p-ANCA, have been extensively investigated for diagnosis and disease stratification.
[New approaches to diagnosing and treating Crohn's disease].
TLDR
Current views on the diagnosis and medical treatment of Crohn's disease are presented and promising treatment options, which affect the key molecules of the pathogenesis of this disease, are considered.
Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease
TLDR
There exists a long delay in a considerable proportion of CD patients, and more public awareness work needs to be done in order to reduce patient and doctor delays in this target population.
Circulating MicroRNA Is a Biomarker of Pediatric Crohn Disease
TLDR
The findings suggest serum miRNAs may prove useful as noninvasive biomarkers in CD, with promising diagnostic utility, with sensitivities for CD above 80%.
Inflammatory bowel disease
TLDR
This presentation of IBD gives a brief overview in the fields of clinical epidemiology and molecular biology, and can clearly support the view that global perspectives in IBD are increasingly important.
Microbial etiology of Inflammatory Bowel Disease: Microbial diversity and the role of Escherichia coli
TLDR
A remarkable increase in the order of unclassified Clostridia was detected in inflamed tissues, particularly in CD patients, and species richness and diversity were the highest in non-inflamed IBD biopsies.
COMPOSITIONS AND METHODS USEFUL FOR THE TREATMENT AND DAGNOSIS OF NFLAMMLATORY BOWEL DISEASE
TLDR
A comparison of microRNA signatures of tumor-dervied exosomes as diagnostic biomarkers of ovarian cancer and that of pediatric Crohn disease shows that microRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2a.
RETRACTED ARTICLE: Mouse models of intestinal inflammation and cancer
TLDR
Potential mechanisms of pathogenesis in inflammatory bowel diseases and celiac disease, as well as those involved in the progression to associated cancers, are highlighted, most of which have been identified from studies utilizing mouse models of intestinal inflammation.
...
...

References

SHOWING 1-10 OF 75 REFERENCES
Serologic markers in inflammatory bowel disease: state of the art.
  • W. Sandborn
  • Medicine
    Reviews in gastroenterological disorders
  • 2004
TLDR
The use of pANCA, ASCA, I2, and Omp C in patients with IBD is reviewed, with a focus on patients with compatible gastrointestinal symptoms.
Serological markers in inflammatory bowel diseases.
This chapter is an overview of the literature on serological markers of inflammatory bowel diseases (IBD), focusing on anti-neutrophil cytoplasm autoantibodies (ANCA) and anti- Saccharomyces
Autoantibodies as predictors of disease.
TLDR
Recognizing the clinical potential of autoantibodies and identifying appropriate populations to screen for such autoantIBs could have rich practical rewards, it is argued.
The value of serologic markers in indeterminate colitis: a prospective follow-up study.
TLDR
Evaluated the value of anti-Saccharomyces cerevisiae antibodies (ASCA) and perinuclear antineutrophil cytoplasmic antibodies (pANCA) to increase diagnostic accuracy in categorizing IC and results so far show that ASCA+/ pANCA- predicts CD in 80% of patients with IC and ASCA-/pANca+ predicts UC in 63.6%.
Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics
TLDR
By taking into account the magnitude of the host immune response, Crohn's disease can now be stratified on an immunological basis into more homogeneous clinically distinct subgroups, characterised by greater uniformity among anatomical distribution of disease and disease behaviour.
Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease
TLDR
In this cohort of infliximab-treated patients, neither ASCA nor pANCA could predict response to treatment, however, the combination pAN CA+/ASCA− might warrant further investigation for its value in predicting nonresponse in patients with refractory luminal disease.
Evaluation of Serologic Disease Markers in a Population-Based Cohort of Patients with Ulcerative Colitis and Crohn's Disease
TLDR
In patients with IBD, the sensitivity of ANCA varied widely in different laboratories, whereas the prevalence of ASCA was similar, and the positive predictive values of the ANCA assay combined with the ASCA assay for ulcerative colitis and Crohn's disease are high enough to be clinically useful.
Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn’s disease
TLDR
The association between ASCA and early surgery was evident in patients requiring surgery for ileal or ileocolonic disease, and patients with Crohn’s disease who are positive for ASCA IgA, IgG, or both may define a subset of patients at increased risk for early surgery.
Utility of serum antibodies in determining clinical course in pediatric Crohn's disease.
  • B. Désir, D. Amre, E. Seidman
  • Medicine, Biology
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2004
...
...